Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ET743 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion. |
| 002 | EXPERIMENTAL | ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion. |
| Name | Type | Description |
|---|---|---|
| ET743 | DRUG | 580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion. |
Inclusion Criteria: * Diagnosis of advanced breast cancer * Prior therapy with anthracycline and taxane (2 types of chemotherapy drugs) * At least one measureable tumor lesion * Adequate bone marrow, hepatic and renal function * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1...
ET743, also known as trabectedin, is an investigational small molecule being studied for the treatment of breast neoplasms, or breast cancer. It is in Phase 2 clinical development and has been evaluated in patients with advanced breast cancer.
ET743 is a small molecule, but its specific molecular target has not been disclosed in the available information. It is being studied for its potential anti-cancer activity in breast cancer.
ET743 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ.
ET743 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not yet approved by regulatory authorities, meaning it remains an investigational drug.
ET743 has been studied in one completed clinical trial, NCT00050427, titled 'A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer.' This Phase 2 trial enrolled 53 female patients aged 18 years and older.
Yes, ET743 is also known as trabectedin. The clinical trial NCT00050427 refers to the drug as ET-743 (Trabectedin), indicating that these names are used interchangeably for the same compound.